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Aminoglycosides continue to be widely used for treating severe infections (EORTC,
1987; Barriere, 1988), despite their limited antibacterial spectrum, their potential for
toxicity and the availability of many other potent antibiotics. Rapid bactericidal
activity against susceptible Gram-negative bacilli, and synergism with /Mactam
compounds, further justifies the continuing popularity of the aminoglycosides. Recent
experimental data have suggested that increasing dosage intervals while maintaining
the usual daily dose would ensure maximum efficacy and limit the development of
nephrotoxicity. However, before endorsing these new schedules, several issues deserve
careful consideration.
With regard to the pharmacodynamics there is strong support for these new regimens.
Various in-vitro and animal models have shown that the higher the concentration of
aminoglycoside in these models, the more effective bacterial killing (Flueckiger, Feller
& Gerber, 1986; Vogelman & Craig, 1986; Dudley & Zinner, 1991). This concentration-
dependent activity favours the concept of increased dosing intervals whereby higher
intermittent doses produce higher peak levels and improved bacterial killing.
Aminoglycosides also produce significant, concentration dependent, post-antibiotic
effects (PAE) against both Gram-positive and Gram-negative organisms (Craig &
Vogelman, 1987). In vivo the PAE is able to maintain inhibition of bacterial growth for
several hours when concentrations fall below the MIC. In mice with impaired renal
function, aminoglycoside pharmacokinetics have been shown to mimic those in man
and ensure antimicrobial activity for approximately 24 h owing to the PAE. As a
consequence, the efficacy of the once daily dosing of amikacin was virtually identical to
that observed after administration of the same daily amount of drug given in two or
four divided doses (Craig, Redington & Ebert, 1991). In addition, it is interesting to
note that synergistic PAEs have been observed with various combinations of /Mactams
and amikacin (Isaksson et al., 1991).
With respect to pharmacokinetics, when comparing the once-daily and twice-daily
regimens of amikacin, most parameters follow an almost linear correlation. With the
former schedule, a small reduction of the volume of distribution over time has been
shown (Van der Auwera, 1991), causing a modest increase in the peak levels of
amikacin during therapy (Viscoli et al, 1991); clinical improvement of the patient may
well account for this trend. With both the conventional and new regimens, the volume
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of distribution for amikacin shows enormous variation among the populations of
patients requiring aminoglycoside therapy for severe infections. Although it seems
advisable to monitor amikacin blood levels the peak and trough levels which should be
achieved for optimal efficacy and minimal toxicity for the once daily regimen remain to
be determined. Pending further clinical evaluation it seems reasonable to avoid trough
levels higher than 5 mg/1 (for amikacin) or 2 mg/1 (for other aminoglycosides). Animal
models have demonstrated that renal uptake of gentamicin, netilmicin and amikacin,
but not that of tobramycin, do not correlate linearly with serum concentrations
(Guiliano et al., 1986; Verpooten et al., 1989; De Broe, Verbist & Verpooten, 1991).
Relatively less of the former three aminoglycosides accumulate in the kidney with
increases in serum concentrations. It is likely that this observation may explain the
lesser nephrotoxicity observed with once-daily regimens, compared to divided daily
dosings, as demonstrated in various animal models (Frame et al., 1977; Reiner,
Bloxham & Thompson, 1978; Powell et al., 1983).
Toxicity is an important issue in the debate over once daily dosing. In patients
treated with netilmicin, the once-daily regimen delayed the occurrence of nephrotoxi-
city in comparison with multiple daily dosing (ter Braak et al., 1990). Of the five studies
dealing with more than 700 paediatric and adult patients, using the conventional
regimen as control, less nephrotoxicity was observed with the once-daily dosing
regimen in one study (P. E. Marik, personal communication), a second study supported
the same trend (using phospholipiduria as the criterion; Tulkens, 1991), while the three
other studies failed to indicate a significant difference (Giamarellou et al., 1991; Mailer
et al., 1991; S. Lauwers, personal communication). However, in considering amino-
glycoside toxicity ototoxicity is also extremely important, since severe irreversible
damage can occur, including deafness. Comparative studies are extremely difficult to
perform and interpret because baseline auditory function is rarely defined in the
severely ill patient requiring aminoglycoside therapy. Furthermore the mechanisms of
aminoglycoside ototoxicity remain unclear; aminoglycoside induced inner ear defects
do not seem to be associated with drug accumulation as in the case of nephrotoxicity
(Tran Ba Huy, Bernard & Schacht, 1981). However, in a population of young females
suffering from pelvic inflammatory disease and without other serious underlying
disease, surveillance by high tone audiometry showed a significant safety advantage
with the once-daily regimen compared to the divided daily schedules of netilmicin
(Tulkens, 1991).
Clinical evaluation of dosing schedules of aminoglycosides with respect to efficacy is
difficult largely because these antibiotics are generally prescribed in combination with
other agents. Four controlled, randomized, open studies are presented in this issue of
the Journal. These patients had various infectious conditions mainly caused by
Gram-negative bacilli, and were most often treated with amikacin plus a /Mactam. One
study favoured once daily dosing (Giamarellou et al., 1991), while the others indicated
similar efficacy of the two regimens (Mailer et al., 1991; Tulkens, 1991; S. Lauwers,
personal communication). Other studies, conducted with netilmicin also showed similar
efficacy (Fan et al, 1988; Hollender et al., 1989). In patients with neutropenia and
various immunodeficiencies, studies published to date are inadequate to assess the
efficacy of the once-daily dosing regimen. A large, randomized, controlled study
comparing amikacin and ceftriaxone (once daily) with amikacin and ceftazidime
(divided dosing) conducted by the European Organization for Research and Treatment
of Cancer (EORTC) International Antimicrobial Therapy Cooperative group is
awaited with interest.
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In conclusion in non-neutropenic patients with proven or suspected Gram-negative
infections for which an aminoglycoside seems appropriate, once daily dosing deserves
serious consideration; studies suggest it to be at least as efficacious and as safe as
conventional dosing regimens. The new regimen has the obvious advantage of greater
convenience, more acceptable to patients, and economic advantages. With regard to
neutropenic patients, the results of on-going studies should be awaited before firm
conclusions can be made.
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